All In Biotech

Drug Trial Radar · NCT05497804

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

REsponse Adapted Combination Therapy Approaches for High-Risk Multiple Myeloma (REACH)

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

17

Actual

Start

Sep 22, 2022

Primary completion

Feb 12, 2026

Study completion Sep 4, 2028

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Aug 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial test whether combination chemotherapy works to improve blood test results in patients with high-risk multiple myeloma. Chemotherapy drugs, such as carfilzomib, daratumumab, lenalidomide, and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help determine if patients who have a small amount of cancer left after the initial treatment, called minimal residual disease, will benefit from the drug combination.

Conditions

  • ISS Stage III Plasma Cell Myeloma
  • Multiple Myeloma

Interventions

  • Bone Marrow Aspiration and BiopsyProcedure

    Undergo bone marrow aspiration and biopsy

  • CarfilzomibDrug

    Given IV

  • Computed TomographyProcedure

    Undergo CT or PET/CT

  • DaratumumabBiological

    Given SC

  • DexamethasoneDrug

    Given IV/PO

  • LenalidomideDrug

    Given PO

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Positron Emission TomographyProcedure

    Undergo PET/CT

  • Multigated Acquisition ScanProcedure

    Undergo MUGA scan

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • EchocardiographyProcedure

    Undergo ECHO

  • Chest RadiographyProcedure

    Undergo chest x-ray

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Sustained Minimal Residual Disease (MRD) NegativityTime frame: 1 year

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic in Arizona

    Scottsdale, Arizona

  • Mayo Clinic

    Jacksonville, Florida

  • Mayo Clinic in Rochester

    Rochester, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.